ACUTE MYELOGENOUS LEUKEMIA Clinical Trial
Official title:
A RANDOMIZED COMPARISON OF TWO DIFFERENT DOSAGES OF DAUNORUBICIN IN INDUCTION TREATMENT OF ACUTE MYELOGENOUS LEUKEMIA
Determine the effects of escalated dose of daunorubicin in induction treatment of adult patients with acute myelogenous leukemia who are younger than 60 years of age.
1. Induction chemotherapy
- For patients randomized to receive regular dose of Daunorubicin (Arm I) will be
given Cytarabine 200 mg/m2/day by continuous iv infusion over 24 hours daily for 7
days along with Daunorubicin 45 mg/m2/day by continuous iv infusion over 24 hours
daily for 3 days.
- For patients randomized to receive higher dose of Daunorubicin (Arm II) will be
given Cytarabine 200 mg/m2/day by continuous iv infusion over 24 hours daily for 7
days along with Daunorubicin 90 mg/m2/day by continuous iv infusion over 24 hours
daily for 3 days.
2. Reinduction chemotherapy
- Bone marrow aspiration and biopsy will be performed on day 14 of induction
chemotherapy. If the bone marrow is hypoplastic and contains no more than 5% blast
cells, further chemotherapy will be deferred and the marrow examination will be
repeated at the time of ANC ≥ 1,500/μl and platelets ≥ 100,000/μl in the
peripheral blood for the evaluation of complete remission. If more than 5% blast
cells persist or if the marrow cellularity in the biopsy specimen exceeds 15%, a
course of reinduction chemotherapy will be given.
- Reinduction chemotherapy consists of Cytarabine 200 mg/m2/day by continuous iv
infusion over 24 hours daily for 5 days along with Daunorubicin 45 mg/m2/day by
continuous iv infusion over 24 hours daily for 2 days in both arms.
3. Postremission therapy
- The same postremission therapy will be given to the patients in both arms.
- Four courses of Cytarabine 3 g/m2 will be administered in a 3-hour iv infusion
every 12 hours (twice daily) on days 1, 3, and 5 for a total of six doses per
course. After the four courses of Cytarabine therapy, patients will receive two
monthly treatments with Cytarabine (200 mg/m2/day by a 3-hour iv infusion for 5
days) and Daunorubicin (45 mg/m2 by rapid iv infusion on the first treatment day).
- If patients have HLA-matched sibling or unrelated donors, allogeneic stem cell
transplantation will be performed.
- A complete remission will be defined as ≤ 5% blasts in a normocellular bone marrow
with ANC ≥ 1,500/μl and platelets ≥ 100,000/μl in the peripheral blood and the
disappearance of all blasts in bone marrow.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01200355 -
Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome
|
Phase 4 | |
Active, not recruiting |
NCT03755414 -
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
|
Phase 1 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Completed |
NCT02543879 -
Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies
|
Phase 1 | |
Completed |
NCT01681537 -
Lenalidomide Plus Chemotherapy for AML
|
Phase 1 | |
Completed |
NCT01385423 -
Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)
|
Phase 1 | |
Terminated |
NCT01193400 -
Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy in AML Patients Age Greater Than or Equal to 60 Years
|
Phase 2 | |
Completed |
NCT00995332 -
Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine
|
Phase 1/Phase 2 | |
Completed |
NCT00981240 -
Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes
|
Phase 1 | |
Completed |
NCT00975975 -
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer
|
Phase 2 | |
Completed |
NCT00726934 -
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
|
N/A | |
Completed |
NCT00378534 -
Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants
|
Phase 2 | |
Completed |
NCT01031498 -
Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting
|
Phase 2 | |
Completed |
NCT00789256 -
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS
|
N/A | |
Completed |
NCT00098033 -
Investigation of Clofarabine in Acute Leukemias
|
Phase 2 | |
Completed |
NCT01020539 -
Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia
|
Phase 1 | |
Not yet recruiting |
NCT04709458 -
Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis
|
Phase 1 | |
Recruiting |
NCT04024241 -
Medium Dose of Cytarabine and Mitoxantrone
|
||
Terminated |
NCT02203773 -
Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)
|
Phase 1 |